CCR-2 Modulating Compounds for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and immunoregulatory disorders, such as rheumatoid arthritis and atherosclerosis, lack effective modulators for chemokine receptors, particularly CCR-2, which are crucial for monocyte recruitment and inflammatory responses.
Innovation Solution
Development of specific compounds that modulate chemokine receptor activity, specifically targeting CCR-2, by inhibiting chemokine binding and reducing inflammatory responses, thereby providing therapeutic benefits for various inflammatory and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for inflammatory disorders are used, then general anti-inflammatory effect is achieved, but specific modulation of chemokine receptor activity is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that target particular chemokine receptors (especially CCR-2) rather than providing non-specific anti-inflammatory action. The compounds incorporate specific substituents (R1-R10 groups) and stereochemical configurations that enable selective binding to chemokine receptors, thereby achieving localized modulation at the receptor level while maintaining therapeutic applicability across different inflammatory conditions.
2Reliability
If chemokine receptor modulators are developed, then monocyte recruitment is reduced, but new therapeutic agents must be synthesized and tested
Solution Approach 1:
The patent applies segmentation by dividing the chemokine receptor modulator into distinct structural components (formula I with specific R1-R10 substituents) that can be systematically varied and optimized. This modular approach allows independent adjustment of pharmacological properties while maintaining the core chemokine receptor binding capability, thereby reducing the complexity of developing new agents through structured chemical modification rather than de novo synthesis.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters (substituents R1-R10, stereochemistry, conformational constraints) to optimize the compound's binding affinity and biological activity. By adjusting these parameters within the formula I framework, the compounds achieve effective monocyte recruitment inhibition without requiring entirely new molecular structures, thus simplifying the development process.
3Reliability
If CCR-2 specific compounds are used, then inflammatory response is targeted, but off-target effects may occur
Solution Approach 1:
The patent applies asymmetry by incorporating chiral centers and specific stereochemical configurations in the compound structure (formula I) that enable selective recognition by CCR-2 receptor. The asymmetric molecular geometry and specific spatial arrangement of substituents create steric hindrance that prevents binding to non-CCR-2 receptors, thereby achieving high selectivity and minimizing off-target effects through three-dimensional molecular differentiation.
Data Source
AI summary
The present invention is directed to compounds of the formula I:(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. The present invention is also directed to intermediates useful in the preparation of formula I compounds.